Pfizer Inc., PFE, FDA Calendar, PDUFA Date

Company Name	Pfizer Inc. PFE
Drug Name	HYMPAVZI (sBLA)
Event Name	FDA decision on HYMPAVZI to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors
Event Date	Q2 2026
Outcome Date
Outcome	Pending
Drug Status	Priority review
Rival Drugs
Market Potential
Other Approvals	HYMPAVZI is already approved for the treatment of adults and adolescents with hemophilia A or B without inhibitors.
News

Return to FDA Calendar

Slide Shows